24 Roy Street
Seattle, WA 98109
Complete this contact form for media, investor relations and partnership/business development inquiries
Please leave this field empty.
* required fields
A Feasibility Study of the EMulate Therapeutics Voyager System in Patients with Recurrent Glioblastoma Multiforme (rGBM). This study is currently recruiting qualified patients.
Abstract presented by Xavier Figueroa, PhD, at Society for Neuro-Oncology 2016 Annual Conference, Scottsdale, AZ on November 19, 2016.
The latest information on publications highlighting EMulate Therapeutics research and advancements.
September 21, 2021
EMulate Therapeutics Announces Positive Pre-Clinical Data for its ulRFE(R) Technology Targeting Acute and Chronic Pain; Demonstrates Excellent Pain Reducing Effects Without the Use of Chemicals or Drugs
August 9, 2021
Hapbee Expands Leadership Team to Support Aggressive Growth Strategy
July 28, 2021
Hapbee Users Log Over 1 Million Hours of Use for Sleep, Focus and Alertness Signals
EMulate Therapeutics Voyager® ulRFE® System for rGBM is an investigational medical device. Limited by United States law to investigational use only.
© EMulate Therapeutics 2021. All rights reserved.